• Taxonomic and histogenetic frameworks repeatedly guided prognosis and treatment choices across tumor types, from gliomas to rectal and renal/prostate cancers, reflecting a common move to biology-driven classification. [5], [7], [8], [9], [14], [15]

• Patterns of tumor spread, especially lymphatic/vascular dissemination, emerge as core determinants of prognosis and therapy planning in colorectal and related cancers. [5], [11], [17]

• Therapeutic paradigms evolve from surgical excisions to radiotherapy and pharmacologic approaches, with early experiments in animals and reporting of outcomes guiding practice. [2], [3], [4], [6], [14], [16], [20]

• Prognostic indicators derived from pathology and tumor biology unify across cancers, guiding expectations of survival, recurrence, and disease progression. [8], [9], [10], [15], [18], [19]

• Large-scale epidemiology and care pattern studies reveal metachronous malignancies, incidence, and long-term cancer care challenges. [13], [18], [19]